Tostran

Quick links to important sections

Tostran

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tostran

Quick Facts

Property Description
Active ingredient Testosterone
Form Transdermal Gel (applied topically)
Pharmacological class Androgen; Hormone Replacement Therapy (HRT)
Common use Testosterone replacement for male hypogonadism
Origin Synthetic (chemically identical to the endogenous hormone)

Tostran: A Definition of the Medicinal Product and Its Type

Tostran is a prescription-only medicine whose active ingredient is Testosterone, a chemically synthesized version of the principal endogenous androgen found in the male body. This medicinal product is classified as an androgen for Hormone Replacement Therapy (HRT). Pharmacological profiles indicate the effectiveness of this synthetic steroid in achieving systemic hormone replacement. Tostran is recognized as a modern, controlled-delivery method for this therapy.

Composition and Form: The Transdermal Gel Identity

The unique attribute of Tostran lies in its dosage form as a high-concentration transdermal gel delivered via a metered-dose pump for cutaneous application. This formulation is designed to improve the bioavailability of the Testosterone compared to some oral forms. Tostran is a single-ingredient product where the Testosterone is integrated into a hydroalcoholic gel base containing ethanol, which acts as a penetration enhancer. The topical route of administration allows for consistent, sustained release of the androgen, which helps avoid the sharp hormonal fluctuations observed with other methods.

General Purpose: What Tostran Is Used to Achieve

Tostran is indicated for Testosterone Replacement Therapy (TRT) in adult men diagnosed with confirmed male hypogonadism, or medically defined low testosterone (low T). This therapy is focused on addressing the underlying hormonal deficit. The general purpose of this replacement is to achieve the restoration of serum testosterone levels to within the normal physiological range, thereby supporting the essential systemic functions that rely on adequate testosterone presence.

What side effects are possible with Tostran?

Tostran: Possible Side Effects and Safety Information

Adverse reactions associated with Tostran are formally classified by regulatory authorities based on system-organ classes and frequency.

Classification Common Adverse Reactions (up to 1 in 10 men)
Skin and Subcutaneous Application site reactions (e.g., erythema, pruritus, xerosis, rash)
Blood System Increased red blood cell count, haemoglobin, and haematocrit (polycythaemia)
Endocrine System Gynaecomastia (breast swelling)
Vascular System Hypertension (increase in blood pressure)
General Peripheral oedema (fluid retention), increase in Prostate-Specific Antigen (PSA) levels, and prostate disorders

Serious adverse reactions documented in regulatory sources include the potential for acceleration of pre-existing prostate cancer and the worsening of Benign Prostatic Hyperplasia (BPH). Post-marketing reports also document the risk of Venous Thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism, in patients using testosterone products.

Safety constraints require specific attention. The transdermal gel carries a unique, label-documented risk of secondary exposure to women and children via skin-to-skin contact, which may lead to virilisation in non-users. Tostran is contraindicated in men with known or suspected breast or prostate cancer. For older adults and those with severe cardiac, renal, or hepatic disease, caution is required due to the increased risk of severe oedema and fluid retention.

Due to the nature of hormonal therapy, long-term use requires periodic monitoring of haematocrit, haemoglobin, and PSA levels to manage recognized risks related to the prostate and blood parameter changes.

Overdose and Emergency Response

The regulatory documentation for Tostran defines the overdose profile primarily through the identification of clinical signs indicating excessive systemic testosterone exposure. No specific antidote is known for this transdermal gel.

Documented Manifestations of Excessive Exposure

The officially documented manifestations that may signal the dose is too high include frequent or persistent erections, irritability or nervousness, nausea, unexplained weight gain, swollen ankle joints (oedema), and changes in breathing patterns (including sleep apnoea).

Required Emergency Actions

Urgent medical attention must be sought immediately if symptoms consistent with a blood clot (Venous Thromboembolism, VTE) occur, such as sudden breathlessness or chest pain. Furthermore, the product must be discontinued immediately if the patient develops severe oedema with congestive heart failure. This serious complication risk is specifically documented as being higher in patients with pre-existing severe cardiac, renal, or hepatic disease.

When non-life-threatening symptoms of excessive dose are noted, the patient must contact their doctor. Management consists of symptomatic and supportive treatment, with the primary procedural action being dose reduction or temporary cessation of therapy, guided by the monitoring of serum testosterone concentration to confirm supra-physiological levels.

Therapeutic Uses of Tostran

What Tostran Treats: Main Uses and Benefits

Tostran is a prescription medicine (a testosterone gel) used as testosterone replacement therapy (TRT) for managing symptoms related to male hypogonadism (testosterone deficiency). It offers supportive therapeutic benefit by addressing symptom groups that create interference with daily stability. It is applied in addressing symptoms that create noticeable physiological strain, and may assist in easing the overall symptom burden associated with the deficiency.

This therapy is indicated specifically for when testosterone deficiency has been confirmed by clinical features and biochemical tests. It is relevant when supportive symptom management is appropriate, and may assist with symptoms of low sex drive, chronic fatigue, diminished energy, and conditions involving the loss of muscle mass.


Key Symptomatic Domains

Tostran is applied across domains where additional symptomatic support is needed, typically during phases when symptoms become more noticeable. This includes supporting the management of symptoms related to sexual function (like low libido) and, in certain scenarios, erectile dysfunction, when these manifestations are due to low hormone levels. It is also relevant for easing systemic symptoms of fatigue and low mood, and supporting physical manifestations.

“It helps address symptom clusters that may become intense or disruptive, supporting the patient during difficult episodes by easing distress.”

Quick Fact: Relief for Systemic Imbalance Tostran is commonly used when symptoms are linked to an overall systemic hormonal imbalance, as opposed to symptoms arising from localized injuries, assisting with maintaining functional stability.

Eligibility and Restrictions for Use

Who Can and Cannot Use Tostran: Official Regulatory Information

Tostran is officially indicated only for adult males with confirmed male hypogonadism (testosterone deficiency). Regulatory documents define specific populations who are strictly ineligible or require caution due to pre-existing conditions.


Absolute Contraindications (Must Not Use)

Use is strictly contraindicated in several groups, including men with known or suspected carcinoma of the breast or prostate. The product is also contraindicated for all women, including those who are pregnant or breastfeeding, due to the potential for harm. Patients with a known hypersensitivity to any ingredient are also ineligible.


Age-Related Eligibility and Conditional Use

Use is not indicated for males under 18 years old, as safety and efficacy have not been established in the pediatric population. In men over 65 years, limited experience is available, and long-term safety data remains insufficient.

Conditional use is required for patients with severe cardiac, renal, or hepatic insufficiency or ischaemic heart disease, necessitating caution and monitoring for complications like fluid retention. Men with Benign Prostatic Hyperplasia (BPH) also require monitoring for symptom worsening.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the product's interaction profile by focusing on specific drug classes that require clinical monitoring or potential dose adjustment of the co-administered agent. No drug-drug combinations are formally listed as contraindicated in the interaction section of the product labeling. Furthermore, regulatory documents do not specify interactions with food, alcohol, or common herbal products.

Documented Interaction Classes

Interaction Entity Official Regulatory Statement Type of Constraint
Oral Anticoagulants May increase anticoagulant activity (potentiation). Mandatory Monitoring: Requires more frequent checks of INR and prothrombin time, particularly upon initiating or stopping Tostran.
Anti-diabetic agents May cause a decrease in blood glucose levels. Dose Adjustment: May necessitate a reduction in the dose of the anti-diabetic medication.
Corticosteroids / ACTH May result in increased fluid retention (oedema). Caution in Specific Populations: Risk of fluid retention is emphasized for patients with pre-existing cardiac, renal, or hepatic disease.

The co-administration of Tostran with these agents is characterized by required procedural constraints to manage potential changes in the co-administered drug's effects. The regulatory basis requires health professionals to monitor specific clinical or laboratory parameters to safely maintain treatment stability.

Mechanism of Action

Tostran is a transdermal testosterone preparation that facilitates the systemic delivery of the endogenous androgen testosterone. Following percutaneous absorption, testosterone enters the systemic circulation and is then transported to target cells throughout the body, including muscle, bone, and brain tissue. Testosterone acts primarily as a receptor agonist.

In responsive cells, testosterone either binds directly to the intracellular androgen receptor (AR), or it is first reduced by 5alpha-reductase into the more potent ligand, 5alpha-dihydrotestosterone (DHT), which then binds to the AR. The ligand-receptor complex subsequently translocates into the cell nucleus. Within the nucleus, this complex functions as a ligand-activated transcription factor, binding to Androgen Response Elements (AREs) on the DNA. This binding initiates or suppresses the transcription of specific target genes. The resulting altered mRNA levels and consequent modified protein synthesis mediate the downstream cellular and physiological effects. At a system level, these processes modulate protein anabolism, influence bone mineral density, and affect erythropoiesis via stimulation of erythropoietin production.

Dosage and Administration Information

Instruction Map: How to Use Tostran — Administration Guidelines

This map consolidates the usage instructions for Tostran (Testosterone 20 mg/g transdermal gel), focusing on administration and dosing protocols.

Category Instruction
Route of administration Topical (Transdermal/Cutaneous application).
Dosing schedule The initial starting dose is 3 g gel per day, corresponding to 60 mg of testosterone. This is delivered by a metered-dose pump.
Maximum Recommended Dose The daily dose must not exceed 4 g gel (80 mg testosterone).
Timing in relation to meals Applied once daily, preferably at approximately the same time each morning; application should occur after washing, bathing, or showering.
Preparation requirements The pump must be primed before the first use by dispensing and discarding a specific number of initial actuations.
Age-group administration rules The product is not indicated for use in males under 18 years of age and is not for use in women.
Missed-dose rules If a dose is missed, apply it as soon as remembered. However, if it is almost time for the next scheduled dose, the missed application should be skipped, and the regular schedule resumed without applying a double dose to compensate.
Special procedural conditions The dose is adjusted based on both clinical signs and serum testosterone concentrations to maintain eugonadal levels.

Instruction Classifications (High-Level)

Classification Detail
Administration method type Topical (Transdermal Gel).
Frequency pattern Once daily (for long-term hormone maintenance).
Basis of protocol Standard clinical and biochemical monitoring.
Use-context constraints Must be applied to clean, dry, intact skin on the designated application sites (abdomen or inner thighs); the gel must not be applied to the genitals.

Resulting Procedural Structure

Step sequence:

  • Prime the pump before the first use by dispensing and discarding the first actuations.
  • Apply the prescribed daily dose once daily to a clean, dry area on the abdomen or inner thighs.
  • Rub the gel gently until dry; wash hands thoroughly with soap and water afterward.
  • Cover the application site with clean clothing once the gel has dried.
  • Titrate the daily dose based on measured testosterone levels, preferably taken 2–4 hours post-application once stabilized.

Connection to the Overall Use Protocol

The instructions establish a precise topical administration protocol that begins with a fixed starting dose of 3 g gel applied once daily to designated skin areas. This protocol mandates dose adjustment be performed according to laboratory test results and clinical response, with a defined maximum daily dose of 4 g gel.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Tostran

The clinical evaluation of testosterone gel, including the formulation known as Tostran, is described by research evidence from authoritative sources. This evidence base consists primarily of randomized controlled trials (RCTs), systematic reviews, and meta-analyses. The focus of these studies is on understanding the patterns observed in men with clinically confirmed low testosterone, or hypogonadism.


Evidence for Core Use in Male Hypogonadism

This section summarizes the structure of the clinical evaluation for testosterone replacement therapy, focusing on the available RCTs, systematic reviews, and the primary outcomes researchers examined, such as biochemical measurement and changes in symptoms like libido and energy.

The research conducted for this indication includes multiple short- to medium-term randomized, placebo-controlled trials. The studies explored patterns of change in measured hormone levels and specific reported symptoms in adult men diagnosed with hypogonadism. Trials reported measurements that described testosterone levels in the observed population moving toward the desired range during the study periods. Researchers also monitored metrics related to sexual desire, energy levels, and overall mood using standardized scales, and studies reported measurements of lean body mass and fat mass over the course of the studies.

Study Focus: Sexual Function, Mood, and Energy

Researchers used specific patient-reported outcomes to examine the experiences of men across domains of sexual function and daily functioning. These trials reported patterns of symptom change across metrics like sexual desire and physical energy, findings that help contextualize changes measured during the study period when evaluated against a placebo.


Evidence in Men with Coexisting Metabolic Conditions

Dedicated research was conducted in subgroups of men with hypogonadism complicated by coexisting Type 2 Diabetes Mellitus or Metabolic Syndrome. The research examined specific metabolic outcomes, including metrics of insulin resistance (such as HOMA-IR) and glycemic control (such as HbA1 c). Trials reported measurements of these metabolic markers over the study time intervals, with findings describing patterns related to changes in indicators of insulin function and blood sugar control.


Long-Term Research and Durability of Response

While many core efficacy trials provide data only for a short-term duration of three to six months, some studies have monitored responses over defined time intervals lasting up to 12 months. Evidence from these studies provides context but not individual predictions, describing group patterns related to the durability of the initial reported changes. However, there is limited information for long-term outcomes beyond one year from large-scale RCTs specifically designed to track low-incidence, long-term events, such as major adverse cardiovascular events (MACE) or bone health.


Limitations and Unanswered Questions in the Evidence

The existing research provides context but not individual predictions, and certain limitations are noted across the evidence landscape. Follow-up durations were limited in many of the core randomized trials, meaning long-term effects are not fully established. Specific to metabolic research, the extent to which reported changes in surrogate biomarkers translate into proportional, long-term reductions in major clinical events is not established by these short-term trials. Furthermore, the results apply only to the populations studied, and findings were mixed or varied across studies when evaluating highly subjective, non-specific outcomes.

Key Studies & References

  1. An updated systematic review and meta-analysis of the effects of testosterone replacement therapy on erectile function and prostate

Frequently Asked Questions (FAQ)

Common questions about Tostran (FAQ)

Q: Is Tostran used to treat low energy or tiredness?

A: Studies conducted to support the use of Tostran examine its effect on various symptoms associated with confirmed low testosterone. Official research reports include the monitoring of metrics related to energy levels and fatigue, using specific scales to measure observed changes.


Q: Does Tostran cause hair loss or thinning?

A: Hair loss or thinning is not listed among the most common adverse reactions in the product's official information. However, the hormonal activity of testosterone can influence hair growth patterns. Changes in hair patterns are typically reviewed by a healthcare professional.


Q: Can Tostran lead to acne or skin irritation?

A: Yes, according to official product information, acne and pimples are documented as possible side effects. It is also common to experience reactions at the application site, such as skin irritation, redness, itching, or a rash.


Q: Can using Tostran affect my mood or emotional state?

A: The product labeling reports that changes to mood and emotional state are possible. These reported changes include mood swings, increased irritability, or aggressive behavior. In some documented cases, patients have experienced depression or feelings of mania.


Q: Is it normal to feel a change in the skin where Tostran is applied?

A: Official product information indicates that specific skin reactions at the application site are generally reported to a healthcare professional. These reported reactions include specific sensations like a burning or prickling feeling, as well as common irritations such as dryness, redness, rash, or itchiness.


Q: Is it safe to use Tostran alongside common blood pressure medication?

A: Regulatory documents indicate that Tostran may potentially cause a rise in blood pressure in some patients. Regulatory warnings indicate that patients with high blood pressure should be managed with professional monitoring.


Q: Do food or drinks affect how Tostran is absorbed?

A: Since Tostran is a transdermal gel applied to the skin, its absorption process bypasses the digestive system. Regulatory summaries do not specify any direct interaction or effect between the gel's absorption and the consumption of food or non-alcoholic drinks.


Q: Does Tostran interact with alcohol consumption?

A: Official regulatory summaries indicate that there is no direct interaction reported between the Tostran gel and alcohol consumption.


Q: How long does it typically take to start feeling the effects of Tostran?

A: The gel is designed to allow the hormone to reach stable concentrations in the bloodstream, which typically occurs within the first few days of daily application. Clinical effectiveness is assessed by monitoring hormone concentrations and observing changes in reported symptoms over the first few months.


Q: Is it possible that Tostran might not work for a patient?

A: The treatment is managed by reviewing the daily dose based on clinical signs and periodic measurements of serum testosterone concentration. If the target hormonal range is not achieved, the dose may be reviewed and potentially adjusted within the regulatory limits.


Q: What happens if Tostran use is suddenly stopped?

A: Because this treatment provides hormonal support, abruptly stopping the medication may potentially lead to withdrawal symptoms. These symptoms, acknowledged in regulatory summaries for this drug class, can include fatigue, restlessness, sleep problems, or feelings of depression due to the sudden change in hormone levels.


Q: What is the usual recommended duration of treatment with Tostran?

A: There is no fixed duration for the course of treatment. The duration is individualized based on the patient's continued clinical benefit and response to the therapy. Official regulatory documents suggest that the need for continued use should be evaluated by a prescriber at least once per year.


Q: Can the effects of Tostran vary significantly between different individuals?

A: Yes, the amount of hormone absorbed can vary somewhat from person to person. Regulatory data estimates that about 10% of the applied dose is typically absorbed across skin of average permeability. This individual variation is one reason why dosage is carefully monitored using blood tests.


Q: Is Tostran considered a type of anabolic steroid?

A: Testosterone, the active ingredient in Tostran, is classified as an androgen. It belongs to the broader category of medications known as anabolic-androgenic steroids (AAS), which are synthetic versions of the natural testosterone hormone.


Q: Is Tostran classified as a controlled substance in all regions?

A: In the United States, the active ingredient, testosterone, is classified as a Schedule III controlled substance under the Controlled Substances Act. This regulatory status reflects the substance's potential for misuse. Legal classifications may vary in other international regions.


Q: Why are regular blood tests sometimes required while using Tostran?

A: Regular blood tests are mandatory to ensure the correct and safe administration of the therapy. These tests check three main areas: testosterone levels (to ensure the dose is effective), haematocrit and haemoglobin (to check for blood thickening), and Prostate-Specific Antigen (PSA) levels (for prostate health).


Q: Can older men (over 65) use Tostran?

A: Official product information notes that men over 65 years old may have an increased risk for developing certain heart, blood vessel, or prostate-related issues. For this age group, treatment requires specific caution and close, ongoing monitoring by a healthcare professional.


Q: Are there any specific pre-existing health conditions that prevent the use of Tostran?

A: Regulatory documents state that the product is strictly contraindicated and must not be used by men with known or suspected breast cancer or prostate cancer. Furthermore, patients with severe heart, kidney, or liver disease, or certain forms of sleep apnea, require specific caution and monitoring.


Q: Does Tostran have a withdrawal period when stopping use?

A: Because Tostran is a hormonal medication, regulatory information on this drug class indicates that ceasing its use may potentially lead to withdrawal symptoms. These symptoms can include fatigue, restlessness, sleep problems, or changes in mood due to the body adjusting to the cessation of external hormone levels.


Q: Is Tostran absorbed into the body quickly or slowly?

A: The transdermal gel is specifically formulated to be absorbed in a sustained and continuous manner. This continuous release is intended to provide stable hormone concentrations in the bloodstream over the full 24-hour dosing period, avoiding a rapid, sharp increase in levels.


Q: Can I use Tostran if I have a history of certain heart issues?

A: Patients with pre-existing conditions, specifically severe heart disease, liver disease, or kidney disease, must use Tostran with caution. This is due to the potential risk of fluid retention (oedema), and these patients require close professional monitoring while on the therapy.


Q: Why is Tostran manufactured as a gel instead of a tablet?

A: The transdermal gel formulation is designed to deliver the hormone in a way that provides consistent and sustained release over 24 hours. This continuous absorption through the skin helps maintain more stable hormone levels in the bloodstream, which is different from the fluctuations that can occur with certain other administration forms.


Q: What are the possible long-term effects of using Tostran for an extended time?

A: Clinical trials have generally established that hormone levels can be maintained effectively for up to approximately six months of treatment. However, official documents note that the evidence from long-term randomized controlled trials specifically designed to track outcomes beyond one year is limited.


Q: Does Tostran affect cholesterol levels or blood lipids?

A: Regulatory information indicates that this class of medicine may potentially affect blood lipid levels. This includes the possibility of lowering HDL (high-density lipoprotein) cholesterol, often referred to as 'good cholesterol.' Patients with pre-existing high cholesterol may require closer monitoring.


Q: Is there a risk of misuse or developing dependence on Tostran?

A: Because testosterone is a controlled substance in many regions (e.g., Schedule III in the US), this status reflects the potential for misuse. Official information on this drug class warns that misuse may be associated with dependence and could result in withdrawal symptoms if the substance is stopped.


Q: What is the maximum length of time Tostran can be used continuously?

A: Official documents do not specify a fixed regulatory maximum duration for continuous treatment. Instead, the therapy may continue for as long as the patient receives clinical benefit. However, the entire treatment plan must be formally evaluated by a prescriber at least once per year.


Q: Can Tostran impact sleep patterns or cause insomnia?

A: Official product information states that some patients have reported experiencing trouble sleeping or insomnia. Furthermore, the development or worsening of sleep apnea (a condition where breathing stops or becomes shallow during sleep) is also listed as a possibility.

How should Tostran be stored and disposed of?

How to Store and Dispose of Tostran: Regulatory Requirements

Official regulatory guidelines define precise conditions for storing and handling Tostran transdermal gel to maintain its stability and integrity.

Storage Requirement Detail
Temperature Range Do not store above 25 C.
Prohibited Environments Do not refrigerate or freeze.
Container Positioning The canister must be stored in an upright position between uses.
Special Handling The gel is officially classified as flammable until it has dried completely.

For stability, the medicinal product has a shelf life of two years. Regarding disposal, the official labeling states there are no special requirements; however, unused or expired product should be discarded in accordance with local pharmaceutical waste regulations. Any gel discarded during the initial priming process must be safely placed in household waste and kept out of the reach of children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Tostran found in:

A-Z Index: